[Definition and standardization of histocompatibility requests depending on patient course and donor type: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) and the Francophone Society of Histocompatibility and Immunogenetics (SFHI)].
Définition et standardisation des bilans d’histocompatibilité en fonction du parcours du patient et du type de donneur : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) et de la Société Francophone d’Histocompatibilité et Immunogénétique (SFHI).
Anticorps anti HLA
Donor probability program
HLA antibodies
HLA typing
Haute résolution
High resolution
Outils de probabilité
Standardisation
Standardization
Typage HLA
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
07
01
2021
revised:
27
01
2021
accepted:
27
01
2021
pubmed:
11
5
2021
medline:
5
1
2022
entrez:
10
5
2021
Statut:
ppublish
Résumé
Standardization of histocompatibility tests for allogeneic hematopoietic cell transplants, harmonization of information transmitted to clinicians are part of quality improvement and optimization of human and economic resources. New HLA typing technologies provide high-resolution information within a reasonable time frame. Knowledge of high-resolution HLA typing for the patient and their relatives is essential for a better interpretation of compatibilities. HLA-DPB1 typing must be considered in transplant field regardless of the donor type. The benefits of using search and match programs are considerable. It saves time and reduces additional typing costs by providing rapid information about the likelihood to identify a matched unrelated donor. A backup therapy considering alternative cell sources or treatment can therefore be quickly implemented. The importance of knowledge and consideration of patient immunization for donor choice was explored in previous workshops of the SFGM-TC (2018 and 2019). The published recommendations remain applicable. The routine follow-up protocol and in case of desensitization will be detailed here. This harmonization must be accompanied by the standardization of information to be returned to the clinician regarding the donor finding possibilities for the patient. This will guarantee a similar quality level in every center.
Identifiants
pubmed: 33966883
pii: S0007-4551(21)00136-3
doi: 10.1016/j.bulcan.2021.01.024
pii:
doi:
Substances chimiques
HLA-DP beta-Chains
0
HLA-DPB1 antigen
0
Types de publication
Journal Article
Practice Guideline
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
S45-S52Informations de copyright
Copyright © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.